Japanese researchers have shown in mice that GlaxoSmithKline's marketed migraine drug Amerge naratriptan could be repurposed to treat spinal and bulbar muscular atrophy. Although the pharma is not saying if it will pursue the new indication for the serotonin (5-HT1D) receptor agonist, the research group is already planning an investigator-led Phase II trial.